Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.40 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20081227 | 0.92 | KIF11 (0.39) | KIF11SLC6A1SLC6A11PSMB8PSMB5 | |
| SCHEMBL24311395 | 0.91 | KIF11 (0.52) | KIF11SLC6A1 | |
| SCHEMBL12603471 | 0.90 | KIF11 (0.38) | KIF11SLC6A1SLC6A11PSMB8PSMB5 | |
| SCHEMBL28736686 | 0.86 | KIF11 (0.37) | KIF11SLC6A1SLC6A11 | |
| SCHEMBL20081230 | 0.80 | SLC6A1 (0.41) | KIF11SLC6A1SLC6A11 | |
| SCHEMBL17488430 | 0.77 | PSMB8 (0.32) | PSMB8PSMB5 | |
| SCHEMBL9211737 | 0.77 | KMT2A (0.42) | PSMB8PSMB5 | |
| SCHEMBL9258692 | 0.77 | PSMB8 (0.37) | PSMB8PSMB5 | |
| SCHEMBL13523659 | 0.75 | KIF11 (0.51) | KIF11 | |
| SCHEMBL1534306 | 0.75 | ALOX12 (0.56) | KIF11SLC6A1SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | GENOSCO INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-07-02 | — | — | US | disclosed |
| US-20200121808-A1 | SSTR-TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | TVA (ABC), LLC | 2020-04-23 | — | — | US | disclosed |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | TARVEDA THERAPEUTICS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20110117009-A1 | DRUG CONJUGATES WITH POLYGLYCEROLS | FREIE UNIVERSITÄT BERLIN (DE) | 2011-05-19 | — | — | US | disclosed |
| WO-2009121564-A1 | DRUG CONJUGATES WITH POLYGLYCEROLS | FREIE UNIVERSITÄT BERLIN (DE) | 2009-10-08 | — | — | WO | disclosed |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2009-02-05 | — | — | US | disclosed |
| EP-1988896-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M Innovative Properties Company (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007100634-A2 | IMMUNE RESPONSE MODIFIER CONJUGATES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-0856007-B1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2004-04-21 | — | — | EP | disclosed |
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
| EP-0856007-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK PATENT GmbH (DE) | 1998-08-05 | — | — | EP | disclosed |
| WO-1997014716-A1 | CYCLOPEPTIDE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109702-A1 | NOVEL GSPT PROTEIN DEGRADER AND APPLICATION THEREOF | CRBN, PSMB3, PSMB1 | KIF11 4340/4885SLC6A1 3284/4885SLC6A11 3757/4885 |
| US-20200121808-A1 | SSTR-TARGETED CONJUGATES ENCAPSULATED IN PARTICLES AND FORMULATIONS THEREOF | SSTR1, SSTR4, SSTR5 | KIF11 1124/4885SLC6A1 903/4885SLC6A11 773/4885 |
| US-10624967-B2 | Targeted conjugates and particles and formulations thereof | SSTR5, SSTR1, SSTR4 | KIF11 988/4885SLC6A1 1239/4885SLC6A11 1214/4885 |
| US-20200206356-A1 | TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF | SSTR5, SSTR1, SSTR4 | KIF11 988/4885SLC6A1 1239/4885SLC6A11 1214/4885 |
| US-20110117009-A1 | DRUG CONJUGATES WITH POLYGLYCEROLS | DDOST, STT3A, STT3B | KIF11 588/4885SLC6A1 2491/4885SLC6A11 1969/4885 |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | KIF11 4588/4885SLC6A1 4569/4885SLC6A11 4483/4885 |
| US-20090035323-A1 | IMMUNE RESPONSE MODIFIER CONJUGATES | IFNG, CD74, MYD88 | KIF11 2020/4885SLC6A1 4758/4885SLC6A11 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.